[ Price : $8.95]
An AdverseEvents study shows that FDA drug alerts and warnings dont lead to increased adverse events reports on those drugs.[ Price : $8.95]
CDER issues a MAPP documenting its System of Record and Office of Business Informatics responsibilities.[ Price : $8.95]
FDA posts a draft guidance on its Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) that describes a risk-ba...[ Price : $8.95]
Federal Register Notice: FDA submits a proposed collection information on data to support drug product communications to the Offic...[ Price : $8.95]
FDAs New Jersey District Office warns Valeant Pharmaceuticals about Quality System Regulation violations in its production of Scul...[ Price : $8.95]
Hale Advisors principal Zoe Dunn writes that FDAs Guidance on Social Media Platforms with Character Space Limitations undermines p...[ Price : $8.95]
Washington Universitys (St. Louis) new associate vice chancellor and director of its new Center for Research Innovation in Busines...[ Price : $8.95]
GlaxoSmithKline reports positive results from a planned analysis of its Phase 3 BREAK-3 study involving Tafinlar (dabrafenib) in 2...